Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.82
(
2.10%
)
Bitcoin
70,960.00
(
-0.37%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: joethdo post# 136757

Thursday, 02/09/2012 10:52:55 AM

Thursday, February 09, 2012 10:52:55 AM

Post# of 257257
The new guidance for operating cash burn excluding collaborative revenue from NVS (effectively reimbursement for MNTA’s R&D) and excluding MNTA’s small Lovenox royalty payable to MIT is $22-28M per quarter.

The above guidance includes an unspecified amount for MNTA’s portion of ongoing legal fees for the Lovenox patent case. (NVS pays 100% of the ongoing legal fees in the Copaxone patent case.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now